2022
Utilization and Survival Impact of Hypofractionated Radiotherapy in Stage I Non-small Cell Lung Cancer
Saeed N, Jin L, Amini A, Verma V, Lester-Coll N, Chen P, Decker R, Park H. Utilization and Survival Impact of Hypofractionated Radiotherapy in Stage I Non-small Cell Lung Cancer. American Journal Of Clinical Oncology 2022, 46: 66-72. PMID: 36662872, DOI: 10.1097/coc.0000000000000974.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Non-Small-Cell LungDose Fractionation, RadiationHumansLung NeoplasmsRadiation Dose HypofractionationRetrospective StudiesConceptsNon-small cell lung cancerStage I non-small cell lung cancerOverall survivalCell lung cancerLung cancerStereotactic body radiation therapyNational Cancer DatabaseLog-rank testBody radiation therapyOptimal fractionation scheduleMultivariable modeling techniquesOS benefitHypofractionated radiotherapySurvival impactMultivariable analysisCox regressionCancer DatabaseRetrospective analysisFractionation schedulesRadiation therapyHFRTPatientsCFRTRadiotherapyKaplan-Meier estimatorImmunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer
Pichert MD, Canavan ME, Maduka RC, Li AX, Ermer T, Zhan PL, Kaminski M, Udelsman BV, Blasberg JD, Park HS, Goldberg SB, Boffa DJ. Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer. JAMA Network Open 2022, 5: e2224478. PMID: 35925606, PMCID: PMC9353596, DOI: 10.1001/jamanetworkopen.2022.24478.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Non-Small-Cell LungCohort StudiesFemaleHumansImmunotherapyLung NeoplasmsMaleNeoplasm StagingConceptsStage III non-small cell lung cancerNon-small cell lung cancerClinical stage III non-small cell lung cancerUnresectable stage III non-small cell lung cancerPropensity-matched sampleGeneral US populationSurvival advantageCohort studyLung cancerMultivariable Cox proportional hazards modelsUS populationStage III lung cancerMedian age 66 yearsCox proportional hazards modelNational Cancer DatabaseEfficacy of immunotherapyAge 66 yearsProtocol rangesCell lung cancerClinical trial populationsProportional hazards modelTerms of ageImmunotherapy initiationImmunotherapy recipientsImmunotherapy use
2021
A reply to “Randomized controlled clinical trial is needed for toxicity of IMRT VS 3D-CRT in PORT for LA-NSCLC”
Jairam V, Soulos PR, Gross CP, Yu JB, Park HS, Decker RH. A reply to “Randomized controlled clinical trial is needed for toxicity of IMRT VS 3D-CRT in PORT for LA-NSCLC”. Lung Cancer 2021, 168: 84-85. PMID: 34933760, DOI: 10.1016/j.lungcan.2021.12.003.Peer-Reviewed Case Reports and Technical NotesMeSH KeywordsCarcinoma, Non-Small-Cell LungHumansLung NeoplasmsRadiotherapy, ConformalRadiotherapy, Intensity-ModulatedClinical Outcomes and Safety Profile in the Treatment of Synchronous Nonmetastatic Lung Tumors With Stereotactic Body Radiation Therapy
Raju SC, Peters GW, Decker RH, Park HS. Clinical Outcomes and Safety Profile in the Treatment of Synchronous Nonmetastatic Lung Tumors With Stereotactic Body Radiation Therapy. Practical Radiation Oncology 2021, 12: e110-e116. PMID: 34861443, DOI: 10.1016/j.prro.2021.11.006.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Non-Small-Cell LungDose Fractionation, RadiationHumansLung NeoplasmsProgression-Free SurvivalRadiosurgeryRetrospective StudiesConceptsStereotactic body radiation therapyPrimary lung tumorsSynchronous primary lung tumorsAdverse events gradeCommon Terminology CriteriaBody radiation therapyLung tumorsNew primaryTerminology CriteriaOverall survivalClinical outcomesLung cancerRadiation therapyEvents gradeEarly-stage primary lung cancerMedian progression-free survivalEffective doseDistant failure ratesLocal failure rateMedian overall survivalMedian total dosePrimary lung cancerProgression-free survivalPatterns of recurrenceNonmetastatic lung cancerPost-operative radiation therapy for non-small cell lung cancer: A comparison of radiation therapy techniques
Jairam V, Pasha S, Soulos PR, Gross CP, Yu JB, Park HS, Decker RH. Post-operative radiation therapy for non-small cell lung cancer: A comparison of radiation therapy techniques. Lung Cancer 2021, 161: 171-179. PMID: 34607209, DOI: 10.1016/j.lungcan.2021.09.010.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsMaleMedicareRadiotherapy DosageRadiotherapy, ConformalRadiotherapy, Intensity-ModulatedUnited StatesConceptsPost-operative radiation therapyNon-small cell lung cancerCell lung cancerRadiation therapyPropensity-score matchingLA-NSCLCCardiac toxicityLung cancerAdvanced non-small cell lung cancerClinical risk factorsProportion of patientsMultivariable logistic regressionPrior treatment historyPredictors of receiptUse of IMRTConformal radiation therapyLong-term toxicityChi-squared testRadiation therapy techniquesRadiotherapy treatment techniquesUpfront surgeryElderly patientsTreatment toxicityMean ageMedicare databaseRates of invasive disease and outcomes in NSCLC patients with biopsy suggestive of carcinoma in situ
Talcott WJ, Miccio JA, Park HS, White AA, Kozono DE, Singer L, Sands JM, Sholl LM, Detterbeck FC, Mak RH, Decker RH, Kann BH. Rates of invasive disease and outcomes in NSCLC patients with biopsy suggestive of carcinoma in situ. Lung Cancer 2021, 157: 17-20. PMID: 34052704, DOI: 10.1016/j.lungcan.2021.05.028.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaBiopsyCarcinoma in SituCarcinoma, Non-Small-Cell LungHumansLung NeoplasmsNeoplasm StagingRetrospective StudiesConceptsNon-small cell lung cancerBiopsy suggestiveInvasive diseaseSitu diseaseSquamous histologySurvival outcomesTumor sizeObserved cohortNational Cancer DatabaseExcellent survival outcomesHalf of patientsCell lung cancerMultivariable logistic regressionResection of lesionsAdenocarcinoma histologyDefinitive therapyNSCLC patientsOverall survivalLocal therapyRisk stratificationLung cancerCancer DatabaseResectionSurgical pathologyLesion size
2020
Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non–small cell lung cancer: A network meta‐analysis of randomized trials
Pathak R, De Lima Lopes G, Yu H, Aryal MR, Ji W, Frumento KS, Wallis CJD, Klaassen Z, Park HS, Goldberg SB. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non–small cell lung cancer: A network meta‐analysis of randomized trials. Cancer 2020, 127: 709-719. PMID: 33119177, DOI: 10.1002/cncr.33269.Peer-Reviewed Original ResearchMeSH KeywordsB7-H1 AntigenCarcinoma, Non-Small-Cell LungHumansImmune Checkpoint InhibitorsLung NeoplasmsNetwork Meta-AnalysisRandomized Controlled Trials as TopicConceptsNon-small cell lung cancerAdvanced non-small cell lung cancerSingle-agent ICICell lung cancerPD-L1Lung cancerAdditional overall survival benefitsEfficacy of chemoimmunotherapyFirst-line ICIHigh PD-L1Overall survival benefitCochrane Central RegisterFirst-line treatmentPD-L1 statusPhase 3 trialLow PD-L1Absence of headSignificant differencesRandom-effects modelBayesian random-effects modelImproved PFSOS benefitEfficacy outcomesEligible trialsCentral RegisterLocal Ablative Therapies for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.
Jairam V, Park HS, Decker RH. Local Ablative Therapies for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer. The Cancer Journal 2020, 26: 129-136. PMID: 32205537, DOI: 10.1097/ppo.0000000000000433.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerLocal ablative therapyOligoprogressive non-small cell lung cancerCell lung cancerAblative therapyMetastatic diseaseLung cancerMetastatic non-small cell lung cancerTime of diagnosisLong-term survivalLimited metastasesOligometastatic diseaseMetastatic patientsSystemic therapyRadiofrequency ablationDisease progressionPatient outcomesStereotactic radiotherapyTherapyPatientsDiseaseAccumulation of evidenceCancerProgressionComplex diseases
2019
Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma
Kann BH, Verma V, Stahl JM, Ross R, Dosoretz AP, Shafman TD, Gross CP, Park HS, Yu JB, Decker RH. Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma. Radiotherapy And Oncology 2019, 134: 44-49. PMID: 31005223, DOI: 10.1016/j.radonc.2019.01.027.Peer-Reviewed Original ResearchConceptsNon-small cell lung carcinomaStereotactic body radiation therapyProgression-free survivalEarly-stage non-small cell lung carcinomaOperable patientsBody radiation therapyCell lung carcinomaOverall survivalLocal failureLung carcinomaRadiation therapyInoperable early stage non-small cell lung carcinomaDefinitive stereotactic body radiation therapyLack of resectionPoor surgical candidacyRetrospective cohort studyKaplan-Meier methodologyHigher overall survivalDisease-related outcomesMulti-institutional analysisDocumentation of patientsStandard of careMulti-institutional studyCohort studyInoperable patients
2018
Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis
Kann BH, Miccio JA, Stahl JM, Ross R, Verma V, Dosoretz AP, Park HS, Shafman TD, Gross CP, Yu JB, Decker RH. Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis. Radiotherapy And Oncology 2018, 132: 188-196. PMID: 30391106, DOI: 10.1016/j.radonc.2018.10.017.Peer-Reviewed Original ResearchConceptsNon-small cell lung carcinomaStereotactic body radiotherapyAdjuvant systemic therapyEarly-stage non-small cell lung carcinomaSystemic therapyMulti-institutional analysisCell lung carcinomaOverall survivalST patientsBody radiotherapyLung carcinomaDefinitive stereotactic body radiotherapyEarly-stage NSCLC patientsClinical risk factorsRetrospective cohort studyKaplan-Meier methodHigher T stageTreatment of patientsMulti-institutional databasePropensity-score matchingPlatinum doubletsST cohortST regimenCohort studyNSCLC patientsAssociation Between Radiation Dose and Outcomes With Postoperative Radiotherapy for N0-N1 Non–Small Cell Lung Cancer
Wang EH, Corso CD, Park HS, Chen AB, Wilson LD, Kim AW, Decker RH, Yu JB. Association Between Radiation Dose and Outcomes With Postoperative Radiotherapy for N0-N1 Non–Small Cell Lung Cancer. American Journal Of Clinical Oncology 2018, 41: 152-158. PMID: 26523443, DOI: 10.1097/coc.0000000000000245.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAgedCarcinoma, Non-Small-Cell LungCohort StudiesDatabases, FactualDisease-Free SurvivalDose-Response Relationship, RadiationFemaleHumansLung NeoplasmsMaleMargins of ExcisionMiddle AgedMultivariate AnalysisNeoplasm InvasivenessNeoplasm StagingPneumonectomyPrognosisProportional Hazards ModelsRadiotherapy DosageRadiotherapy, AdjuvantRadiotherapy, Intensity-ModulatedRetrospective StudiesSurvival AnalysisTreatment OutcomeConceptsNon-small cell lung cancerPostoperative radiotherapyCell lung cancerIntensity-modulated radiation therapyPORT doseOverall survivalLung cancerRadiation therapyUse of PORTNational Cancer Data BaseStage IIProportion of patientsGroup of patientsProportional hazards regressionEvidence of benefitSurgical resectionWorse survivalMultivariable analysisHazards regressionRetrospective studyConformal radiationPatientsRadiotherapy techniquesRadiation modalitiesModern treatment
2017
Stage I Lung SBRT Clinical Practice Patterns
Corso CD, Park HS, Moreno AC, Kim AW, Yu JB, Husain ZA, Decker RH. Stage I Lung SBRT Clinical Practice Patterns. American Journal Of Clinical Oncology 2017, 40: 358-361. PMID: 25503436, DOI: 10.1097/coc.0000000000000162.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Non-Small-Cell LungDatabases, FactualHumansLung NeoplasmsPractice Patterns, Physicians'RadiosurgeryRadiotherapy DosageRetrospective StudiesUnited StatesConceptsStereotactic body radiation therapyNational Cancer DatabaseStage I non-small cell lung cancer patientsUse of SBRTNon-small cell lung cancer patientsCell lung cancer patientsStage I NSCLCMajority of patientsClinical practice patternsLung cancer patientsBody radiation therapyMedian BED10SBRT useDosing guidelinesRetrospective studyCancer patientsPrescription trendsCancer DatabasePractice patternsRadiation therapyPatientsDose prescriptionGyRegimensCommon prescription
2016
Elderly patients undergoing SBRT for inoperable early-stage NSCLC achieve similar outcomes to younger patients
Mancini BR, Park HS, Harder EM, Rutter CE, Corso CD, Decker RH, Husain ZA. Elderly patients undergoing SBRT for inoperable early-stage NSCLC achieve similar outcomes to younger patients. Lung Cancer 2016, 97: 22-27. PMID: 27237023, DOI: 10.1016/j.lungcan.2016.04.011.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Non-Small-Cell LungFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedNeoplasm StagingRadiosurgeryRetrospective StudiesSurvivalTreatment OutcomeConceptsNon-small cell lung cancerEarly-stage non-small cell lung cancerStereotactic body radiation therapyNon-elderly patientsElderly patientsDistant controlOverall survivalYounger patientsInoperable early-stage non-small cell lung cancerUse of SBRTStage non-small cell lung cancerLocal controlMultivariable Cox proportional hazards analysisCox proportional hazards analysisGrade 5 toxicityNon-elderly cohortProportional hazards analysisCell lung cancerRisk of complicationsRate of efficacyBody radiation therapyLogistic regression analysisLate gradeAcute gradeSurgical resection
2015
Comparison of survival outcomes among standard radiotherapy regimens in limited-stage small cell lung cancer patients receiving concurrent chemoradiation
Rutter CE, Park HS, Corso CD, Yeboa DN, Mancini BR, Lester-Coll NH, Kim AW, Decker RH. Comparison of survival outcomes among standard radiotherapy regimens in limited-stage small cell lung cancer patients receiving concurrent chemoradiation. Lung Cancer 2015, 90: 243-248. PMID: 26277031, DOI: 10.1016/j.lungcan.2015.08.002.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerDose-fractionation regimensLimited-stage small cell lung cancerConcurrent CRTConcurrent chemoradiationOverall survivalLimited-stage small-cell lung cancer patientsProportional hazardsSmall cell lung cancer patientsMultivariable Cox proportional hazardsCell lung cancer patientsOptimal radiotherapy doseOngoing randomized trialsInferior overall survivalKaplan-Meier analysisCell lung cancerLarger tumor sizeMedian survival timeLung cancer patientsCox proportional hazardsStandard radiotherapy regimensLarge national datasetChemoradiation regimensSimilar OSEquivalent OSAngiotensin-converting enzyme inhibitors decrease the risk of radiation pneumonitis after stereotactic body radiation therapy
Harder EM, Park HS, Nath SK, Mancini BR, Decker RH. Angiotensin-converting enzyme inhibitors decrease the risk of radiation pneumonitis after stereotactic body radiation therapy. Practical Radiation Oncology 2015, 5: e643-e649. PMID: 26412341, DOI: 10.1016/j.prro.2015.07.003.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyACE inhibitor useNonsteroidal anti-inflammatory drugsAngiotensin receptor blockersRadiation pneumonitisSymptomatic radiation pneumonitisInhibitor useBody radiation therapyAnti-inflammatory drugsRadiation therapyReceptor blockersACE inhibitorsAngiotensin-converting enzyme inhibitor useACE inhibitor usersCommon Terminology CriteriaEnzyme inhibitor usePrimary lung cancerNormal lung tissuesAvailable medical recordsCox proportional hazardsPulmonary doseTerminology CriteriaInhibitor usersAdverse eventsOverall survivalPostoperative Radiation Therapy Is Associated With Improved Overall Survival in Incompletely Resected Stage II and III Non–Small-Cell Lung Cancer
Wang EH, Corso CD, Rutter CE, Park HS, Chen AB, Kim AW, Wilson LD, Decker RH, Yu JB. Postoperative Radiation Therapy Is Associated With Improved Overall Survival in Incompletely Resected Stage II and III Non–Small-Cell Lung Cancer. Journal Of Clinical Oncology 2015, 33: 2727-2734. PMID: 26101240, DOI: 10.1200/jco.2015.61.1517.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungDatabases, FactualFemaleHumansKaplan-Meier EstimateLogistic ModelsLung NeoplasmsMaleMiddle AgedNeoplasm StagingNeoplasm, ResidualPneumonectomyRadiotherapy DosageRadiotherapy, AdjuvantRadiotherapy, ConformalRadiotherapy, Intensity-ModulatedRegistriesRetrospective StudiesTreatment OutcomeUnited StatesConceptsUse of PORTPostoperative radiotherapyOverall survivalNodal stageStage IIMultivariable analysisPatient populationLung cancerNon-small cell lung cancerOverall American Joint CommitteeNational Cancer Data BaseImproved overall survivalLower nodal stagePostoperative radiation therapyPositive surgical marginsAmerican Joint CommitteeCancer stage IICell lung cancerProportional hazards regressionMultivariable logistic regressionClinicopathologic covariatesChemotherapy receiptPerioperative mortalityOnly patientsSuch patientsPatients Selected for Definitive Concurrent Chemoradiation at High-volume Facilities Achieve Improved Survival in Stage III Non–Small-Cell Lung Cancer
Wang EH, Rutter CE, Corso CD, Decker RH, Wilson LD, Kim AW, Yu JB, Park HS. Patients Selected for Definitive Concurrent Chemoradiation at High-volume Facilities Achieve Improved Survival in Stage III Non–Small-Cell Lung Cancer. Journal Of Thoracic Oncology 2015, 10: 937-943. PMID: 25738221, DOI: 10.1097/jto.0000000000000519.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultCarcinoma, Non-Small-Cell LungChemoradiotherapyCohort StudiesFemaleHumansLung NeoplasmsMaleMiddle AgedNeoplasm StagingRetrospective StudiesSurvival AnalysisYoung AdultConceptsDefinitive concurrent chemoradiation therapyConcurrent chemoradiation therapyHigh-volume facilitiesNon-small cell lung cancerStage III NSCLC patientsCell lung cancerOverall survivalNSCLC patientsLung cancerStage III non-small cell lung cancerHigher Charlson-Deyo comorbidity scoresCharlson-Deyo comorbidity scoreNational Cancer Data BaseCox proportional hazards regressionFacility case volumeImproved overall survivalAdvanced nodal stageDefinitive concurrent chemoradiationKaplan-Meier analysisPopulation-based survivalMultivariable logistic regressionProportional hazards regressionRisk of deathIntensity-modulated radiotherapyAcademic affiliationCentral versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell Lung Cancer
Park HS, Harder EM, Mancini BR, Decker RH. Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell Lung Cancer. Journal Of Thoracic Oncology 2015, 10: 832-837. PMID: 25634007, DOI: 10.1097/jto.0000000000000484.Peer-Reviewed Original ResearchConceptsStereotactic body radiotherapyBiological equivalent doseCentral tumor locationCell lung cancerOverall survivalTumor locationCentral tumorsLocal controlLung cancerBody radiotherapyPrimary non-small cell lung cancerNon-small cell lung cancerMultivariable logistic regression modelingMultivariable Cox regression modelingInoperable early stageProximal bronchial treeInferior overall survivalCox regression modelingKaplan-Meier analysisWorse overall survivalPeripheral tumor locationRegression modelingLogistic regression modelingAcute gradeCT1-2N0M0
2014
Prophylactic Cranial Irradiation for Patients With Locally Advanced Non–Small-Cell Lung Cancer at High Risk for Brain Metastases
Park HS, Decker RH, Wilson LD, Yu JB. Prophylactic Cranial Irradiation for Patients With Locally Advanced Non–Small-Cell Lung Cancer at High Risk for Brain Metastases. Clinical Lung Cancer 2014, 16: 292-297. PMID: 25499149, DOI: 10.1016/j.cllc.2014.11.005.Peer-Reviewed Original ResearchConceptsProphylactic cranial irradiationLA-NSCLC patientsSequential landmark analysesCell lung cancerBrain metastasesHigh riskCranial irradiationSurvival benefitLung cancerLandmark analysisEffect of PCICox proportional hazards regressionNon-PCI patientsOverall survival benefitEnd Results (SEER) databaseHigh-risk patientsStage III NSCLCGroup of patientsProportional hazards regressionLog-rank testSignificant survival differenceImmortal time biasPopulation-based analysisAdult patientsOnly patients